| Code | CSB-RA015779MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to fulranumab, targeting nerve growth factor (NGF), a neurotrophin essential for the development, maintenance, and survival of peripheral sensory and sympathetic neurons. NGF plays a critical role in pain signaling by binding to its receptors TrkA and p75NTR, promoting neuronal sensitization and contributing to chronic pain conditions. Elevated NGF levels have been implicated in various painful disorders, including osteoarthritis, chronic lower back pain, and inflammatory pain states, making it an important therapeutic target for pain management research.
Fulranumab is a fully humanized IgG2 kappa monoclonal antibody that was developed for the treatment of chronic pain through NGF neutralization. By binding to NGF with high affinity, it prevents NGF from interacting with its receptors, thereby blocking downstream pain signaling pathways. This biosimilar antibody serves as a valuable research tool for investigating NGF-mediated mechanisms in pain pathophysiology, neurobiology studies, and the evaluation of anti-NGF therapeutic strategies in preclinical models.
There are currently no reviews for this product.